Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Victoza on Insulinogenic Indices in Healthy Volunteers
NCT02089256Phase 4Completed
- Sponsor
- University of Tartu
- Start
- Jun 2014
- Primary completion
- Mar 2015
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4, open-label trial of liraglutide in type 2 diabetes mellitus (T2DM), sponsored by University of Tartu. Primary endpoint: Change in the glucose-sensitivity of the beta cells at 3 weeks. Started Jun 2014; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02089256.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02089256.